@article {Wang:2017:1550-7033:911,
title = "Nanomedicines in Bone CancerFrom Diagnostics to Therapies",
journal = "Journal of Biomedical Nanotechnology",
parent_itemid = "infobike://asp/jbn",
publishercode ="asp",
year = "2017",
volume = "13",
number = "8",
publication date ="2017-08-01T00:00:00",
pages = "911-930",
itemtype = "ARTICLE",
issn = "1550-7033",
url = "https://www.ingentaconnect.com/content/asp/jbn/2017/00000013/00000008/art00004",
doi = "doi:10.1166/jbn.2017.2396",
keyword = "BONE CANCER, DIAGNOSTIC, METASTASIS, NANOMEDICINE, DRUG DELIVERY",
author = "Wang, Quan and Hu, Wei and Cai, Leyi and Huang, Yixing and Qian, Zhiyong",
abstract = "
Bone primary cancer and bone metastases from other tumors pose a threat to millions of people in the world. The developments of nanomedicines have offered unprecedented opportunities to advance the treatment of various diseases, including bone cancer. In this review, we examine
recent developments in nanomaterials for bone cancer therapy, in terms of their applications in bone cancer diagnostics and therapies, as well as in model simulation. Taking advantage of their inherent properties and modified with kinds of bioactive ligands, a broad range of nanomedicines
based on metallic, lipidic, polymeric, and inorganic nanomaterials have been developed to target bone tumors in vivo and intended for use either as contrast agents for diagnostic imaging or as therapeutic agents in chemotherapy, hyperthermia therapy, photodynamic therapy and photothermal
therapy. Moreover, a growing number of biological models with nanomedicines for bone cancer have been developed to study the underlying mechanisms for primary bone tumor and cancer bone metastasis. As cancer nanomedicines are a multidisciplinary area of research including material engineering,
pharmacy, tumor biology and clinical medicine, it needs efforts to bridge the knowledge gaps between different areas.",
}